An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma - Concepedia

Concepedia

Publication | Open Access

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

DOI Full Paper Access

41

Citations

17

References

2018

Year

John M. Burke, Andrei R. Shustov, James Essell, Dipti Patel‐Donnelly, Jay Yang, Robert Chen, Wei Ye, Wen Shi, Sarit Assouline, Jeff P. Sharman

Clinical Lymphoma Myeloma & Leukemia

References

	Year	Citations

Page 1